ArticleTranslational vision science & technology2025
A Deep Learning Model for Detecting the Eyes Receiving Glaucoma Medications Using Anterior Segment Images.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: We aimed to investigate whether a deep learning model can detect eyes receiving glaucoma medications from anterior segment images and to visualize the anatomical areas prioritized during classification. Methods: The training dataset was comprised of 20,000 augmented images of eyes receiving or not receiving glaucoma medications. The test dataset was comprised of 100 images each of eyes receiving and not receiving glaucoma medications. Diagnostic performance of the model was evaluated using the area under the receiver operating characteristic curve (AROC) and compared with human recognition. Subgroup analyses were performed based on conjunctival hyperemia, prostaglandin analog use, and illumination conditions. Gradient-Weighted Class Activation Mapping (Grad-CAM) was applied to explore anatomical areas prioritized by the model. Results: The deep learning model detected the eyes receiving glaucoma medications with significantly higher accuracy than human recognition (AROC, 0.90 vs. 0.75; P < 0.01). No significant AROC differences were observed in the presence or absence of conjunctival hyperemia, prostaglandin analog use, or under varying illumination. Grad-CAM analysis revealed the periocular area was significantly more frequently highlighted in eyes receiving glaucoma medication than in those not receiving medication (P < 0.01). Conclusions: The deep learning model objectively detected glaucoma medication use based on anterior segment images. Saliency mapping suggests that the model can identify subtle periocular changes induced by treatment. Translational Relevance: The deep learning model will contribute to assessing the severity of side-effects of glaucoma medications and facilitate the development of eye drops with improved tolerability.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.